RedShift BioAnalytics
PrivateLast Round
Series E
Oct 18, 2021
Total Funding Raised
$70.18M
Momentum
Top 50%
of companies Caplight tracks
Company Overview
RedShift BioAnalytics operates in Healthcare & Life Sciences and is based in Boxborough, Massachusetts. Its latest recorded funding round was a Series E round in October 2021.
RedShift BioAnalytics is a life sciences company that provides a platform for biomolecule analysis through its proprietary Microfluidic Modulation Spectroscopy (MMS) technology.
Sector
Healthcare & Life Sciences
Verticals
Biotech Equipment, Biotechnology, Drug Discovery, Medical Devices
Business Model
B2B
Customer Profile
Hardware Sales, Services & Consulting, Hardware + Subscription
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
RedShift BioAnalytics Comparables
Compare RedShift BioAnalytics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Unchained Labs | 82% | |
| Fida Biosystems | 78% | |
| NanoTemper Technologies | 77% |
For institutional investors. Book with your work email.
RedShift BioAnalytics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series E | Oct 18, 2021 | ||||
| Series D Extension | Feb 18, 2021 | ||||
| Series D | Jan 29, 2020 | ||||
| Series C | Mar 8, 2017 | ||||
| Series B | Apr 11, 2013 | ||||
Series A | Jan 12, 2006 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
RedShift BioAnalytics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Technology Venture Partners | Series E, Series A, Series B, Series C, Series D Extension, Series D |
| Waters Corporation | Series D Extension, Series D, Series E, Series C |
| Illumina Ventures | Series E |
Market signals
Structured signals derived from secondary market and firmographic data.
- Jul 20, 2026
Open roles increased to 10, 5x the trailing average.
- Jun 2, 2025
Monthly visitors increased 82% MoM, reaching 6.2K.
For institutional investors. Book with your work email.
RedShift BioAnalytics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about RedShift BioAnalytics's valuation, stock price, and market status.
Is RedShift BioAnalytics a public or private company?
RedShift BioAnalytics is a private company.
What is the current stock price of RedShift BioAnalytics?
RedShift BioAnalytics is a private company, so its shares have no public market price. Caplight tracks RedShift BioAnalytics's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is RedShift BioAnalytics worth (valuation)?
Valuation information for RedShift BioAnalytics is not publicly available.
Can I buy RedShift BioAnalytics stock?
RedShift BioAnalytics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was RedShift BioAnalytics's last funding round?
RedShift BioAnalytics's most recent funding round was Series E on October 18, 2021.
Who are the main investors in RedShift BioAnalytics?
Key investors in RedShift BioAnalytics include Technology Venture Partners, Waters Corporation, Illumina Ventures.
Will RedShift BioAnalytics IPO soon?
No public IPO plans have been announced for RedShift BioAnalytics.
How can I track RedShift BioAnalytics secondary market activity?
Caplight tracks bids, offers, and trades in RedShift BioAnalytics's shares on secondary markets.